摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-2-(3,4-Dimethoxy-phenyl)-3-(4-fluoro-phenyl)-acrylonitrile | 64560-07-2

中文名称
——
中文别名
——
英文名称
(Z)-2-(3,4-Dimethoxy-phenyl)-3-(4-fluoro-phenyl)-acrylonitrile
英文别名
2-(3,4-Dimethoxyphenyl)-3-(4-fluorophenyl)prop-2-enenitrile
(Z)-2-(3,4-Dimethoxy-phenyl)-3-(4-fluoro-phenyl)-acrylonitrile化学式
CAS
64560-07-2
化学式
C17H14FNO2
mdl
——
分子量
283.302
InChiKey
HFWYCGBGOHDKNC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    42.2
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Asymmetric synthesis of phenanthroindolizidine alkaloids with hydroxyl group at the C14 position and evaluation of their antitumor activities
    摘要:
    The asymmetric total synthesis of the strongly cytotoxic phenanthroindolizidine alkaloid 3 was achieved. Using the same route, various derivatives were also synthesized. Cytotoxicity of those synthetic compounds was evaluated and compounds 19, 23, and 27 demonstrated potent cytotoxicities similar to that of 3. The in vivo antitumor efficacy of selected compounds was also evaluated and 23 demonstrated moderate antitumor efficacy. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.11.008
  • 作为产物:
    参考文献:
    名称:
    Asymmetric synthesis of phenanthroindolizidine alkaloids with hydroxyl group at the C14 position and evaluation of their antitumor activities
    摘要:
    The asymmetric total synthesis of the strongly cytotoxic phenanthroindolizidine alkaloid 3 was achieved. Using the same route, various derivatives were also synthesized. Cytotoxicity of those synthetic compounds was evaluated and compounds 19, 23, and 27 demonstrated potent cytotoxicities similar to that of 3. The in vivo antitumor efficacy of selected compounds was also evaluated and 23 demonstrated moderate antitumor efficacy. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.11.008
点击查看最新优质反应信息

文献信息

  • Breast cancer resistance protein (bcrp) inhibitor
    申请人:Yamazaki Ryuta
    公开号:US20060128636A1
    公开(公告)日:2006-06-15
    The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH 3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR 1 (R 1 is hydrogen or C1-C4 alkyl), —O(CH 2 ) n COOR 2 (n=1−7: R 2 is hydrogen or C1-C4 alkyl), —OOCCH 2 CH 2 COOR 3 (R 3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH) 2 ) or a salt thereof, a sulfate group (i.e., —OSO 3 H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.
    本发明提供了一种抑制BCRP的药物。一种含有以下式(1)所表示的二苯乙烯腈衍生物作为活性成分的乳腺癌耐药蛋白抑制剂:[其中,8个R分别表示氢原子、羟基、硝基、氨基、乙酰氨基(—NHCOCH3基)、氰基(—CN基)、甲酰基(—CHO基)、—COOR1(R1为氢或C1-C4烷基)、—O(CH2)nCOOR2(n = 1-7:R2为氢或C1-C4烷基)、—OOCCH2CH2COOR3(R3为氢、C1-C4烷基、(Z)-2-(3,4-二甲氧基苯基)-3-(4-羟基苯基)-丙烯腈或葡萄糖基)、C1-C8烷氧基、C1-C4烷基、卤原子、C1-C4烷氧基C1-C4烷氧基C1-C4烷氧基、C2-C8酰氧基、C2-C8卤代酰氧基、亚甲二氧基基团、三氟甲基基团、磷酸酯基团(即—OP(O)(OH)2)或其盐、硫酸酯基团(即—OSO3H)或其盐、葡萄糖基或其盐、葡萄糖基的磷酸酯或酯的盐、葡萄糖基的硫酸酯或酯的盐,或者是它的酯或盐。
  • STILBENE DERIVATIVE AND STILBENE ANALOG DERIVATIVE, AND USE THEREOF
    申请人:MORINAGA MILK INDUSTRY CO., LTD.
    公开号:EP0640586A1
    公开(公告)日:1995-03-01
    A compound with a 12-lipoxygenase inhibitor activity, represented by general formula (I), a precursor therefor, and a medicine containing the same, wherein R¹ represents hydrogen or hydroxy; one of R² and R³ represents hydrogen, while the other cyano; and Ar represents (a), (b) or (c), wherein R⁴ represents hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl or cyano.
    由通式(I)表示的具有 12-脂氧合酶抑制剂活性的化合物、其前体以及含有该化合物的药物,其中 R¹ 代表氢或羟基;R² 和 R³ 中的一个代表氢,另一个代表氰基;Ar 代表(a)、(b)或(c),其中 R⁴ 代表氢、低级烷基、低级烷氧基、卤素、三氟甲基或氰基。
  • BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR
    申请人:KABUSHIKI KAISHA YAKULT HONSHA
    公开号:EP1591117A1
    公开(公告)日:2005-11-02
    The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (-NHCOCH3 group), a cyano group (-CN group), a formyl group (-CHO group), -COOR1 (R1 is hydrogen or C1-C4 alkyl) , -O(CH2)nCOOR2 (n=1-7: R2 is hydrogen or C1-C4 alkyl) , -OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., -OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., -OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.
    本发明提供了一种抑制 BCRP 的药物。 一种乳腺癌抗性蛋白抑制剂,其活性成分含有下式(1)所代表的二苯基丙烯腈衍生物: [其中,8 个彼此相同或不同的 R 的每一个代表氢原子、羟基、硝基、氨基、乙酰氨基(-NHCOCH3 基)、氰基(-CN 基)、甲酰基(-CHO 基)、-COOR1(R1 是氢或 C1-C4 烷基)、-O(CH2)nCOOR2(n=1-7:R2是氢或C1-C4烷基),-OOCCH2CH2COOR3(R3是氢、C1-C4烷基、(Z)-2-(3,4-二甲氧基苯基)-3-(4-羟基苯基)-丙烯腈或吡喃糖基),C1-C8烷氧基,C1-C4烷基、C1-C4 烷氧基、C2-C8 酰氧基、C2-C8 卤代酰氧基、亚甲基二氧基、三氟甲基、磷酸基团(即e.,-OP(O)(OH)2)或其盐、硫酸基(即-OSO3H)或其盐、吡喃糖基或其盐、吡喃糖基的磷酸酯或其酯盐、吡喃糖基的硫酸酯或其酯盐、哌啶基哌啶羰基氧基]、其酯或其盐。
  • US5589506A
    申请人:——
    公开号:US5589506A
    公开(公告)日:1996-12-31
  • US7371773B2
    申请人:——
    公开号:US7371773B2
    公开(公告)日:2008-05-13
查看更多

同类化合物

(E,Z)-他莫昔芬N-β-D-葡糖醛酸 (E/Z)-他莫昔芬-d5 (4S,5R)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4R,4''R,5S,5''S)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (1R,2R)-2-(二苯基膦基)-1,2-二苯基乙胺 鼓槌石斛素 高黄绿酸 顺式白藜芦醇三甲醚 顺式白藜芦醇 顺式己烯雌酚 顺式-桑皮苷A 顺式-曲札芪苷 顺式-二苯乙烯 顺式-beta-羟基他莫昔芬 顺式-a-羟基他莫昔芬 顺式-3,4',5-三甲氧基-3'-羟基二苯乙烯 顺式-1,2-二苯基环丁烷 顺-均二苯乙烯硼酸二乙醇胺酯 顺-4-硝基二苯乙烯 顺-1-异丙基-2,3-二苯基氮丙啶 阿非昔芬 阿里可拉唑 阿那曲唑二聚体 阿托伐他汀环氧四氢呋喃 阿托伐他汀环氧乙烷杂质 阿托伐他汀环(氟苯基)钠盐杂质 阿托伐他汀环(氟苯基)烯丙基酯 阿托伐他汀杂质D 阿托伐他汀杂质94 阿托伐他汀内酰胺钠盐杂质 阿托伐他汀中间体M4 阿奈库碘铵 银松素 铒(III) 离子载体 I 钾钠2,2'-[(E)-1,2-乙烯二基]二[5-({4-苯胺基-6-[(2-羟基乙基)氨基]-1,3,5-三嗪-2-基}氨基)苯磺酸酯](1:1:1) 钠{4-[氧代(苯基)乙酰基]苯基}甲烷磺酸酯 钠;[2-甲氧基-5-[2-(3,4,5-三甲氧基苯基)乙基]苯基]硫酸盐 钠4-氨基二苯乙烯-2-磺酸酯 钠3-(4-甲氧基苯基)-2-苯基丙烯酸酯 重氮基乙酸胆酯酯 醋酸(R)-(+)-2-羟基-1,2,2-三苯乙酯 酸性绿16 邻氯苯基苄基酮 那碎因盐酸盐 那碎因[鹼] 达格列净杂质54 辛那马维林 赤藓型-1,2-联苯-2-(丙胺)乙醇 赤松素 败脂酸,丁基丙-2-烯酸酯,甲基2-甲基丙-2-烯酸酯,2-甲基丙-2-烯酸